文献速递白血病

维奈克拉联合克拉屈滨、伊达比星和阿糖胞苷(CLIA-VEN)在新诊断急性髓系白血病中较传统7+3化疗获得更高缓解率且不增加毒性

Venetoclax combined with cladribine, idarubicin, cytarabine (CLIA-VEN) results in higher remission rates over conventional 7 + 3 chemotherapy without increased toxicity in newly diagnosed acute myeloid leukaemia.
PubMed 文献 · Br J Haematol · 2025-11-12

本回顾性单中心研究比较了新诊断成人急性髓系白血病患者接受CLIA-VEN方案(n=20,2023-2025年)与历史7+3方案(n=42,2016-2023年)的结局。CLIA-VEN组第28天复合完全缓解率(90% vs 54.8%,p=0.002)和微小残留病阴性复合完全缓解率(93.8% vs 40.9%,p<0.001)均更高,且≥2级终末器官毒性和早期死亡率未增加。倾向性评分逆概率治疗加权分析显示CLIA-VEN与总生存改善相关(p=0.002)。

要点

  • CLIA-VEN组第28天复合完全缓解率90%,7+3组54.8%(p=0.002)。
  • CLIA-VEN组微小残留病阴性复合完全缓解率93.8%,7+3组40.9%(p<0.001)。
  • ≥2级终末器官毒性两组无显著差异(45% vs 59.5%,p=0.28)。

核心结论

  • 作者认为,CLIA-VEN较当前新诊断急性髓系白血病标准治疗疗效更高、不增加毒性,并可能延长生存,但承认回顾性单中心研究的局限性。

研究设计与样本

  • 回顾性单中心研究,比较连续接受CLIA-VEN的新诊断成人急性髓系白血病患者(n=20,2023-2025年)与接受7+3的历史队列(n=42,2016-2023年)。
  • 中位年龄54岁(四分位距42-63岁),男性占54%,58%为欧洲白血病网(ELN)2022 adverse-risk疾病。

主要发现

  • 第28天复合完全缓解率CLIA-VEN组90% vs 7+3组54.8%(p=0.002)。
  • 第28天微小残留病阴性复合完全缓解率CLIA-VEN组93.8% vs 7+3组40.9%(p<0.001)。
  • 任何≥2级终末器官毒性CLIA-VEN组45% vs 7+3组59.5%(p=0.28),未增加。
  • 早期死亡率CLIA-VEN组0% vs 7+3组16.7%(p=0.09),未增加。
  • 采用倾向性评分指导的逆概率治疗加权平衡基线人口学特征后,接受CLIA-VEN与总生存改善相关(p=0.002)。

局限性

  • 原文明确承认这是一项回顾性单中心研究,存在相关局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Induction chemotherapy in fit de novo acute myeloid leukaemia (AML) patients has historically combined an anthracycline with standard-dose cytarabine ('7 + 3') despite complete response (CR) rates of 50%-70%. In May 2023, our institution adopted the utilization of cladribine, cytarabine, idarubicin and venetoclax (CLIA-VEN) for intensive remission-induction therapy. In this retrospective study, outcomes of newly diagnosed adult AML patients who were consecutively treated with CLIA-VEN (n = 20; 2023-2025) were compared to a historical cohort that received 7 + 3 (n = 42; 2016-2023). The median interquartile range [IQR] age was 54 [42-63] years, 54% were male and 58% had European LeukemiaNet (ELN) 2022 adverse-risk disease. CLIA-VEN was associated with a higher cumulative incidence of composite CR (CCR) (90% vs. 54.8%; p = 0.002) and minimal residual disease (MRD)-negative CCR (93.8% vs. 40.9%; p < 0.001) at 28 days. Any grade ≥ 2 end-organ toxicity (45% vs. 59.5%; p = 0.28) and early mortality (0% vs. 16.7%; p = 0.09) were not increased with CLIA-VEN. Utilizing propensity score guided inverse probability treatment weighting to balance baseline demographics, receipt of CLIA-VEN was associated with improved overall survival (p = 0.002). Acknowledging the limitations of a retrospective single-centre study, our data suggest that CLIA-VEN has higher efficacy without increasing toxicity and the potential to prolong survival compared to the current standard of care in de novo AML patients.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Lee BJ, Griffin SP, Doh J, et al. Venetoclax combined with cladribine, idarubicin, cytarabine (CLIA-VEN) results in higher remission rates over conventional 7 + 3 chemotherapy without increased toxicity in newly diagnosed acute myeloid leukaemia. Br J Haematol. 2025. PMID: 41224356. doi:10.1111/bjh.70253

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。